Investment Thesis
Aclaris is a development-stage biopharmaceutical company with severely deteriorating fundamentals: revenue collapsed 58% YoY to just $2M while operating losses exceed $22M annually. Despite a solid balance sheet (low debt, $28.7M cash), the company is burning ~$18M in operating cash annually, providing less than 2 years of runway. Without evidence of near-term revenue inflection or successful pipeline advancement, the deteriorating commercial performance and mounting losses present significant risk.
Strengths
- Strong liquidity position with 4.03x current ratio and $28.7M cash reserves
- Conservative balance sheet with minimal leverage (0.07x debt-to-equity ratio)
- Improved loss per share metrics (69% YoY improvement, though still negative)
Risks
- Dramatic 58% YoY revenue decline indicates failed commercialization or lost revenue sources
- Severe cash burn of $18.1M in operating cash flow with only ~1.6 years of runway remaining
- Extreme unprofitability with net margins of -993% and operating losses of -$22.2M on minimal revenue base
- Suspicious 162% gross margin suggests non-core revenue sources rather than sustainable product sales
- No evidence of profitable path or near-term revenue stabilization
Key Metrics to Watch
- Quarterly revenue trajectory and stabilization of commercial products
- Monthly cash burn rate and updated cash runway projections
- Pipeline advancement milestones and potential FDA approvals or commercial launches
- Operating cash flow improvement and path to cash flow breakeven
Financial Metrics
Revenue
2.0M
Net Income
-19.8M
EPS (Diluted)
$-0.15
Free Cash Flow
-18.2M
Total Assets
198.7M
Cash
28.7M
Profitability Ratios
Gross Margin
162.4%
Operating Margin
-1,111.8%
Net Margin
-993.2%
ROE
-13.8%
ROA
-10.0%
FCF Margin
-909.9%
Balance Sheet & Liquidity
Current Ratio
4.03x
Quick Ratio
4.03x
Debt/Equity
0.07x
Debt/Assets
27.7%
Interest Coverage
N/A
Long-term Debt
10.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:27:16.127530 |
Data as of: 2026-03-31 |
Powered by Claude AI